Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Fallopian Tube Endometrioid Adenocarcinoma 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 12Pemetrexed 6Radiotherapy 5Platinum 4Doxorubicin 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Mitomycin 3Gemcitabine 3Decitabine 3pembrolizumab 2Vinorelbine 2SS1(dsFv)PE38 2Interferon-gamma 2Gene Expression Profiling 2Erlotinib Hydrochloride 2Depsipeptides 2Cyclophosphamide 2Celecoxib 2sargramostim 1rilotumumab 1ranpirnase 1methoxyamine 1entinostat 1decitabine and cedazuridine drug combination 1cixutumumab 1belinostat 1atezolizumab 1anetumab ravtansine 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma, Malignant × anetumab ravtansine × Clear all
NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
49 enrolled 20 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡